Fecal proteolytic profiling of pediatric inflammatory bowel disease: A pilot study
The FASEB Journal · 2024
DOI: 10.1096/fj.202302190r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2024. Verfasst von Wieke Haak und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral Biochemistry, Academic Centre for Dentistry Amsterdam, University of Amsterdam and VU University Amsterdam, Amsterdam, The Netherl…. Hauptthemen laut MEDLINE: Feces, Inflammatory Bowel Diseases, Proteolysis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The Dutch Digestive Foundation (MLDS), Maag Lever Darm Stichting.
Abstract (Originalsprache)
Colonoscopy is the gold standard for diagnosing inflammatory bowel disease (IBD). However, this invasive procedure has a high burden for pediatric patients. Previous research has shown elevated fecal amino acid concentrations in children with IBD versus controls. We hypothesized that this finding could result from increased proteolytic activity. Therefore, the aim of this study was to investigate whether fecal protease‐based profiling was able to discriminate between IBD and controls. Protease activity was measured in fecal samples from patients with IBD (Crohn's disease (CD) n = 19; ulcerative colitis (UC) n = 19) and non‐IBD controls ( n = 19) using a fluorescence resonance energy transfer (FRET)‐peptide library. Receiver operating characteristic (ROC) curve analysis was used to determine the diagnostic value of each FRET‐peptide substrate. Screening the FRET‐peptide library revealed an increased total proteolytic activity (TPA), as well as degradation of specific FRET‐peptides specifically in fecal samples from IBD patients. Based on level of significance ( p < .001) and ROC curve analysis (AUC > 0.85), the fluorogenic substrates W‐W, A‐A, a‐a, F‐h, and H‐y showed diagnostic potential for CD. The substrates W‐W, a‐a, T‐t, G‐v, and H‐y showed diagnostic potential for UC based on significance ( p < .001) and ROC analysis (AUC > 0.90). None of the FRET‐peptide substrates used was able to differentiate between protease activity in fecal samples from CD versus UC. This study showed an increased fecal proteolytic activity in children with newly diagnosed, treatment‐naïve, IBD. This could lead to the development of novel, noninvasive biomarkers for screening and diagnostic purposes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral Biochemistry, Academic Centre for Dentistry Amsterdam, University of Amsterdam and VU University Amsterdam, Amsterdam, The Netherlands.
- Department of Pediatric Gastroenterology, Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
- Department of Pediatric Gastroenterology, Emma Children's Hospital, Amsterdam UMC, Academic Medical Centre, Amsterdam, The Netherlands.
- Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism Research Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
ORCID-Profile: Floris J Bikker, Henk S Brand, Nanne K H de Boer, Wendy E Kaman
Förderung
- The Dutch Digestive Foundation (MLDS)
- Maag Lever Darm Stichting
Zitieren
APA
Haak, W., Jagt, J. Z., de Meij, T. G. J., Bikker, F. J., Brand, H. S., de Boer, N. K. H., & Kaman, W. E. (2024). Fecal proteolytic profiling of pediatric inflammatory bowel disease: A pilot study. The FASEB Journal. https://doi.org/10.1096/fj.202302190r
Vancouver
Haak W, Jagt JZ, de Meij TGJ, Bikker FJ, Brand HS, de Boer NKH, et al. Fecal proteolytic profiling of pediatric inflammatory bowel disease: A pilot study. The FASEB Journal. 2024. doi:10.1096/fj.202302190r
BibTeX
@article{Haak2024,
author = {Haak, Wieke and Jagt, Jasmijn Z and de Meij, Tim G J and Bikker, Floris J and Brand, Henk S and de Boer, Nanne K H and Kaman, Wendy E},
title = {Fecal proteolytic profiling of pediatric inflammatory bowel disease: A pilot study},
journal = {The FASEB Journal},
year = {2024},
doi = {10.1096/fj.202302190r}
}
EUVIMED